does semaglutide lower your immune system affect Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review Researchers highlight the Semaglutide and Tirzepatide: A Look

In the Phase 2 trial, nausea occurred in about 40 to 50 percent of participants at higher doses

Given the rising public interest, potential supply challenges, and safety concerns, this study aimed to assess the current prevalence of GLP-1 and GLP-1/GIP medication use and level of interest in using these medications for weight loss among the adult population in Great Britain

We further examined whether acute tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist recently approved by the FDA for obesity, and retatrutide, an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors currently in Phase 3 trials would recapitulate or enhance these effects

Satoh, J., Kohara, N., Sekiguchi, K

Nature 566 , 115119 (2019)

Some say its genetic thinning that was always there but became visible after fat loss